Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

16/11/2016 - 2 minutes

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology.

Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive record of partnerships, the company is now closing a deal with the big pharma Bristol-Myers Squibb to discover microbiome-related biomarkers, drug targets and therapeutic molecules for cancer therapies and diagnostics.

BMS will pay Enterome €14M ($15M) upfront, R&D funding, milestone payments and royalties for each candidate, although no details have been released. With this partnership, BMS expects to strengthen its immuno-oncology pipeline and improve patient outcomes by harnessing the close relationship between the microbiome and immune regulation.

As we discussed with Pierre Belichard, Enterome’s CEO, medical microbiomics is a rapidly growing field that may hold the key to personalized therapy. In the last decade, research has identified strong links between gut bacteria and human health.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member